Patients and methods
In March 1991, this 40 year old woman developed progressive weakness and paraesthesia in her limbs, and difficulty walking. Twelve weeks later, she was placed on prednisone (60 mg/day) and her decline stopped, but she did not improve. Plasma exchange and HIg produced no clinical change. In July, cyclosporin-A was started at 5 mg/kg/day, and within two weeks she improved (figure). Prednisone was gradually reduced and discontinued in September 1992. She developed hypertension in November 1992. By December 1993, she had only minimal distal weakness and sensory deficit. Cyclosporin-A was tapered off slowly and by January 1995 her dose was 100 mg/day (1 5 mg/kg/day) but with a cyclosporin-A trough concentration of < 19 ng/ml. In April 1995, distal weakness and sensory loss reappeared, and so cyclosporin-A was reinstituted at 400 mg daily (5 mg/kg/day).
Discussion
Three patients with CIDP either improved or were able to discontinue prednisone after starting treatment with cyclosporin-A. In the other five, cyclosporin-A had no effect. This parallels the results in the other studies of similar size,2 5 in which cyclosporin-A was useful mainly in patients who previously responded to prednisone. In addition, two patients relapsed during the clinical monitoring.
There are several past reports of cyclosporin-A being used in limited numbers of patients with CIDP. 46 8 A clear conclusion was not evident from these reports. Tindall5 treated 10 patients with CIDP, all on concurrent prednisone, with cyclosporin-A starting at 5 mg/kg/day. After eight weeks, all patients were started on a fixed steroid taper. By six months, six had improved clinically and it was possible to lower the prednisone dose by amounts ranging from 12% to 100%. Four did not change appreciably. Long term follow up data are not available. Hodgkinson and colleagues2 described eight patients with CIDP, five with MGUS, who received cyclosporin-A. All had received or were receiving other treatments. Cyclosporin-A was started at 10 mg/kg/day, tapering to a dose of 5 mg/kg/day after three months. Three patients went into complete remission. In the other five, the prednisone and plasma exchange requirements were reduced by cotreatment with cyclosporin-A.
The mechanism of action of cyclosporin-A is unclear but the drug is thought to suppress the response of T helper lymphocytes by inhibiting production of interleukin-2 and interferon-y and preventing further recruitment of activated helper cells. Cyclosporin-A thus inhibits the response of T cells to antigens but has little effect on B lymphocytes. It has a rapid onset of action, usually within weeks. Its major side effects are nephrotoxicity and hypertension, both of which can be effectively managed by close clinical monitoring, use of a twice a day dosing regimen, employment of starting doses of 5 mg/kg or less, and frequent monitoring of serum cyclosporin-A and creatinine concentrations. In our study, there were no serious side effects of treatment with cyclosporin-A.
An important question is which clinical characteristics predict a favourable outcome with cyclosporin-A treatment. From previous reports, those patients already responsive to prednisone had the most favourable response to cyclosporin-A. Cyclosporin-A has rarely been effective either as the primary treatment or in patients resistant to other treatments; it has worked mainly as a steroid-sparing agent. This is similar to the clinical experience with azathioprine (AZA) in CIDP. Compared with AZA, cyclosporin-A has a more rapid onset of action and is less allergenic. Although cyclosporin-A can be more toxic than AZA, careful monitoring should increase its safety.
The limited data on patients with CIDP treated with cyclosporin-A make it difficult to evaluate its efficacy. At present, it should be reserved for those patients who are resistant to established treatments, or intolerant of their side effects. Caution must be taken when using cyclosporin-A in elderly patients with
